


COPY OF PAPERS
ORIGINALLY FILED



03 CO

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.



Date:

July 19, 2002

Robin Torres

(Type or print name of person mailing paper)

Robin Torres
(Signature of person mailing paper)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of)	Group Art Unit: 1633
)	Attorney Docket No. 240.1PCD
Cihlar, Tomas)	Examiner: unassigned
)	
Serial No: 10/086,816)	Customer No. 25000
)	
Filed: February 28, 2002)	
)	
Title: NOVEL GENE ENCODING)	
ORGANIC ANION TRANSPORTER)	

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR
AMINO ACID SEQUENCE DISCLOSURES**

Assistant Commissioner for Patents
Washington, D.C. 20231
Box SEQUENCE

Dear Sir:

This is in response to the "Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures". Applicants respectfully submit the following information (which is attached to this transmittal):

- 1) One ASCII diskette containing the Sequence Listing;
- 2) A paper copy of the Sequence Listing;

3) A "Statement to Support Filing and Submission in Accordance with 37 C.F.R. §§ 1.821 – 1.825; and

4) A copy of the "Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures".

Applicants believe that no extension of term or other fees are required. If, however, any extension or fee is required, please charge Account No. 07-1250.

Respectfully submitted,


By: Max D. Hensley
Max D. Hensley
Registration No. 27,043


Date: 7/18/02

Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404
Telephone: (650) 522-5878
Facsimile: (650) 522-5575
email: max_hensley@gilead.com

DISK TO STIC

DATE: _____





**COPY OF PAPERS
ORIGINALLY FILED**

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/086,816	02/28/2002	Tomas Cihlar	240.1PCD

CONFIRMATION NO. 3270

FORMALITIES LETTER



OC00000008156243

25000
GILEAD SCIENCES INC
333 LAKESIDE DR
FOSTER CITY, CA 94404

Date Mailed: 05/20/2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*



Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE